Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non‐small cell lung cancer patients
Open Access
- 27 February 2015
- journal article
- Published by Wiley in Thoracic Cancer
- Vol. 6 (5) , 620-628
Abstract
Background: Even after curative resection, the prognosis of pathological stage I non‐small cell lung cancer (NSCLC) can be heterogeneous, and the use of adjuvant chemotherapy in these patients is controversial. We aimed to identify the prognostic factors and role of adjuvant chemotherapy in pathological stage I NSCLC.Methods: We retrospectively analyzed the correlations between clinicopathological factors and survival in 179 patients with resected pathological stage I NSCLC.Results: After a median follow‐up of 93 months, overall and disease‐free survival were not significantly different between pathological stage IA (n = 138) and IB (n = 41) patients. The prognosis of pathological stage I patients with poorly differentiated tumors was significantly worse than that of those with non‐poorly differentiated tumors (P = 0.003). Multivariate analysis revealed that poor tumor differentiation was an independent factor for poor survival (hazard ratio = 6.889). A marginally significant survival benefit was observed in poorly differentiated pathological stage I patients who received adjuvant chemotherapy (P = 0.053).Pathological stage IA patients who received adjuvant chemotherapy had a worse prognosis than those who did not receive adjuvant chemotherapy (P < 0.001), whereas pathological stage IA patients with poorly differentiated tumors who received adjuvant chemotherapy had better survival than who did not receive adjuvant chemotherapy (P < 0.001).Conclusions: Poor differentiation is an independent prognostic factor in pathological stage I NSCLC after surgical resection. Adjuvant chemotherapy may be beneficial in poorly differentiated pathological stage IA NSCLC patients.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancerJournal of Cardiothoracic Surgery, 2013
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung CancerJournal of Clinical Oncology, 2010
- Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsJournal of Clinical Oncology, 2008
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung CancersJournal of Thoracic Oncology, 2008
- Prognostic factors for survival of stage I nonsmall cell lung cancer patientsCancer, 2007
- Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non–small cell lung carcinomaThe Annals of Thoracic Surgery, 2004
- Histological determinants of survival in completely resected T1-2N1M0 nonsmall cell cancer of the lungThe Annals of Thoracic Surgery, 2004
- Preoperative Evaluation of Patients Undergoing Lung Resection SurgeryaChest, 2003
- Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer: An analysis in each pathologic stageThe Journal of Thoracic and Cardiovascular Surgery, 1995